Characterization and Distribution of Niosomes Containing Ursolic Acid Coated with Chitosan Layer
Overview
Authors
Affiliations
Background And Purpose: Ursolic acid (UA) exhibits anti-hepatocarcinoma and hepatoprotective activities, thus promising as an effective oral cancer therapy. However, its poor solubility and permeability lead to low oral bioavailability. In this study, we evaluated the effect of different ratios of Span 60-cholesterol-UA and also chitosan addition on physical characteristics and stability of niosomes to improve oral biodistribution.
Experimental Approach: UA niosomes (Nio-UA) were composed of Span 60-cholesterol-UA at different molar ratios and prepared by using thin layer hydration method, and then chitosan solution was added into the Nio-UA to prepare Nio-CS-UA.
Findings/results: The results showed that increasing the UA amount increased the particle size of Nio-UA. However, the higher the UA amount added to niosomes, the lower the encapsulation efficiency. The highest physical stability was achieved by preparing niosomes at a molar ratio of 3:2:10 for Span 60, cholesterol, and UA, respectively, with a zeta-potential value of -41.99 mV. The addition of chitosan increased the particle size from 255 nm to 439 nm, as well as the zeta-potential value which increased from -46 mV to -21 mV. Moreover, Nio-UA-CS had relatively higher drug release in PBS pH 6.8 and 7.4 than Nio-UA. In the study, the addition of chitosan produced higher intensities of coumarin-6-labeled Nio-UA-CS in the liver than Nio-UA.
Conclusion And Implications: It can be concluded that the ratio of Span 60-cholesterol-UA highly affected niosomes physical properties. Moreover, the addition of chitosan improved the stability and drug release as well as oral biodistribution of Nio-UA.
Badran M, Alsubaie A, Bekhit M, Alomrani A, Almomen A, Ibrahim M Saudi Pharm J. 2024; 32(12):102208.
PMID: 39697473 PMC: 11653644. DOI: 10.1016/j.jsps.2024.102208.
Chimplee S, Mitsuwan W, Zulkifli M, Eawsakul K, Ongtanasup T, Sangkanu S PeerJ. 2024; 12:e18452.
PMID: 39559326 PMC: 11572385. DOI: 10.7717/peerj.18452.
Alali U, Mohammed Kadhim Al-Tuma M, Fadhil Jawad A, Talib Ahmed S, Addai Ali H, Abdulzehra S Asian Pac J Cancer Prev. 2024; 25(7):2539-2550.
PMID: 39068589 PMC: 11480629. DOI: 10.31557/APJCP.2024.25.7.2539.
Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds.
Fadaei M, Fadaei M, Kheirieh A, Rahmanian-Devin P, Dabbaghi M, Nazari Tavallaei K EXCLI J. 2024; 23:212-263.
PMID: 38487088 PMC: 10938253. DOI: 10.17179/excli2023-6868.
Tulbah A, Elkomy M, Zaki R, Eid H, Eissa E, Ali A Int J Pharm X. 2023; 6:100206.
PMID: 37637477 PMC: 10458293. DOI: 10.1016/j.ijpx.2023.100206.